Remember in the mid-90s when we didn't have any coverage except for 1 biotech news letter?
We've been here, done that!
IMO, at this price, the greatest return now will come to the investor, not the trader. IMGN is LONG overdue for a few things to go right for a change.
With the increased knowledge of how our bodies actually work, and the combined efforts of our partners, I really think things will get better than the price reflects down here. Analysts will "initiate" coverage once again as good things pan out -- the same ones that at one point recommended us, and that have been following us for years by covering our partners.